证券代码：002332 证券简称：仙琚制药 编号：2023-011 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 ☐业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 其他（电话会） 参与单位名称及人员姓名 安信基金 博道基金 博时基金 淳厚基金 淡水泉 德邦基金 东吴基金 东兴基金 东证资管 国盛证券 富国基金 高毅资产 光大资管 国华兴益 国融自营 国寿养老 国泰基金 国调基金 国新证券 海通自营 恒立基金 红土创新 宏鼎投资 华宝基金 汇添富 惠升基金 建信投资 健顺投资 金泊投资 金鹰基金 金元顺安 进化论资管 玖鹏资产 凯石基金 明世伙伴 纽富斯 农银人寿 勤辰私募 青骊投资 青榕资产 趣时资产 泉果基金 人保资产 冰河资产 润晖投资 泰旸资产 上银基金 金泊投资 太平养老 泰康香港 天弘基金 同泰基金 万家基金 西部利得 西藏德传 禧弘基金 仙人掌基金 兴银理财 亚太财险 野村资管 益民基金 银杏环球 长江资管 长信基金 招商信诺 浙江仙琚制药股份有限公司投资者关系活动记录表 招商资管 正圆投研 中海基金 中信证券 中信资本 中意资产 中邮基金 中再资产 pinpoint 时间 20 ...

证券代码：002332 证券简称：仙琚制药 浙江仙琚制药股份有限公司投资者关系活动记录表 编号：2023-009 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） 线上、线下参加由浙江省国资委和深圳证券交易所共同组 | | | 织召开的"地方国企焕新颜——在浙里 看国企"上市大 | | 参与单位名称及人员姓名 | 厅集体业绩说明会暨浙江国有上市公司2022年度集体业 | | | 绩说明会全体投资者。 | | 时间 | 2023年05月17日 15:00-17:40 | | 地点 | 深圳证券交易所上市大厅、深交所"互动易"平台 | | | （http://irm.cninfo.com.cn） | | | 财务总监 王瑶华 | | 上市公司接待人员姓名 | 董事会秘书 张王伟 | | | 独立董事 刘斌 | | 投资者关系活动主要内容 | 本次业绩说明会分为两个部分，第一部分，公司董事 会秘书张王伟先生就公司基本情况、经营概况及企业 ...

证券代码：002332 证券简称：仙琚制药 公告编号：2023-025 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2023年4月26日发布了《2022 年年度报告》、《2023年一季度报告》，为便于广大投资者深入全面地了解公司情 况，公司将举办投资者接待日活动，现将有关事项公告如下： 一、活动时间 2023年5月23日（星期二）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2023年5月22日（上午8:30-11:00，下午14:00-16:00）与公司 董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和安 排。 联系人：沈旭红 高晶 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长张宇松先生、总经理金炜华先生、财务总监王瑶华女士、董事会秘书张 王伟先生（如有特殊情况，参与人员会有调整）。 五、注意事 ...

浙江仙琚制药股份有限公司 关于参加深圳证券交易所上市大厅集体业绩说明会的公告 证券代码：002332 证券简称：仙琚制药 公告编号：2023-024 浙江仙琚制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为进一步加强公司与投资者的沟通交流，促进投资者深入了 解公司经营情况、未来发展战略等，公司将参加由浙江省国资委和深圳证券交易 所共同组织召开的"地方国企焕新颜——在浙里 看国企"上市大厅集体业绩说 明会暨浙江国有上市公司 2022 年度集体业绩说明会，同时就公司 2022 年度业绩 情况与投资者互动交流。现将有关事项公告如下： 一、本次业绩说明会的安排 1、召开时间：2023 年 5 月 17 日（周三）下午 15：00 至 17：40 2、召开地址：深圳证券交易所上市大厅 3、召开方式：图文与直播视频转播 4、公司出席人员： 财务总监王瑶华，独立董事刘斌，董事会秘书张王伟。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导 ...

证券代码：002332 证券简称：仙琚制药 浙江仙琚制药股份有限公司投资者关系活动记录表 编号：2023-008 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2022年度业绩说明会的全体投资者 | | 时间 | 2023年04月28日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 董事长 上市公司接待人员姓名 | 张宇松 | | 总经理 | 金炜华 | | | 财务总监 王瑶华 | | | 董事会秘书 张王伟 | | | 独立董事 张红英 | | 投资者关系活动主要内容 | 1. 请公司拆分一下制剂业务中妇科、麻醉、呼吸、皮肤、普 药的毛利率，以及原料药业务中国内和国外业务的毛利率，谢 谢 | | 介绍 | 答:您好！感谢您的提问。从产品毛利率来看，皮质激素 | | | 毛利率53.97%，妇科及计生用 ...

Financial Performance - The company's operating revenue for the first quarter was CNY 957,286,011.96, a decrease of 8.75% compared to CNY 1,049,027,960.34 in the same period last year[16] - Net profit attributable to shareholders of the listed company was CNY 133,111,920.61, an increase of 4.23% from CNY 127,713,332.35 year-on-year[16] - The net cash flow from operating activities reached CNY 69,164,061.26, a significant increase of 1,065.20% compared to CNY 5,935,810.00 in the previous year[16] - Total operating income for the period was 957,286,011.96 yuan, a decrease of 8.75% compared to 1,049,027,960.34 yuan in the same period last year[24] - Total operating costs decreased by 11.69% to 794,203,612.80 yuan from 898,974,340.09 yuan in the previous year[24] - Sales expenses decreased by 30.09%, a reduction of 95.19 million yuan, mainly due to a decrease in marketing expenses[33] - Financial expenses decreased by 123.96%, a reduction of 7.29 million yuan, mainly due to decreased interest expenses and increased interest income[33] - Other income increased by 375.81% year-on-year, an increase of CNY 0.8857 million, mainly due to an increase in other operating income[39] - Other expenses decreased by 83.9% year-on-year, a decrease of CNY 4.6737 million, mainly due to the suspension of operations at Haisheng Company in the previous year[39] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,917,547,289.10, reflecting a growth of 2.66% from CNY 6,738,173,286.59 at the end of the previous year[16] - Total liabilities amounted to CNY 1.2664 billion, an increase from CNY 1.2307 billion at the beginning of the year[43] - Total equity remained stable at CNY 2.6512 billion, unchanged from the previous period[43] - Equity attributable to shareholders of the listed company was CNY 5,604,999,529.18, up 2.70% from CNY 5,457,448,911.92 year-on-year[16] - Other receivables increased by 42.24% compared to the beginning of the year, an increase of 29.92 million yuan, mainly due to the increase in other temporary payments[18] - Accounts receivable increased by 42.6% compared to the beginning of the year, an increase of CNY 1.5397 million, mainly due to an increase in accepted bills received during the collection of payments[39] - Prepayments increased by 219.14% compared to the beginning of the year, an increase of CNY 48.6421 million, primarily due to an increase in prepayments according to contracts[39] Cash Flow - Cash flow from operating activities was 69,164,061.26 yuan, significantly up from 5,935,810.00 yuan in the same period last year[26] - Cash flow from investment activities showed a net outflow of 33,293,931.92 yuan, compared to a net outflow of 63,740,310.49 yuan in the previous year[26] - Cash flow from financing activities was not detailed in the report[26] - Cash paid for debt repayment decreased by 82.2%, down CNY 53,713,400.00, attributed to reduced cash outflows for debt repayment[4] - Cash paid for dividends, profits, or interest decreased by 72.8%, down CNY 2,337,200.00, mainly due to reduced interest payments[4] - Cash received from borrowings decreased by 100% year-on-year, a decrease of CNY 110.8 million, mainly due to a reduction in borrowings in the current period[53] Shareholder Information - Zhejiang Xianju Pharmaceutical Co., Ltd. reported a total of 213,221,808 shares held by the largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd.[54] - The second largest shareholder, Li Qinjian, holds 23,307,900 shares, representing a significant stake in the company[54] - The company has a diverse shareholder base, with notable investments from various funds, including 19,649,937 shares held by China Construction Bank's fund[54] - The financial report indicates a strong interest from institutional investors, with several funds holding over 11 million shares each[54] Future Outlook - The first quarter report for 2023 is expected to provide insights into the company's performance and future outlook[57] - The company is focusing on expanding its market presence and enhancing its product offerings in the pharmaceutical sector[58] - Future guidance will likely include projections for revenue growth and strategic initiatives in research and development[58] - The company is actively pursuing new technologies and product innovations to strengthen its competitive position[58] - Market expansion strategies are being discussed to capture a larger share of the pharmaceutical market[58] - The company is considering potential mergers and acquisitions to enhance its growth trajectory and market reach[58] Other Financial Metrics - Investment income decreased by 133.6% year-on-year, down CNY 4,708,900.00, primarily due to reduced profits from associated companies[4] - Credit impairment losses increased by 47.36%, up CNY 2,829,200.00, mainly due to increased provisions for bad debts[4] - The basic and diluted earnings per share remained at CNY 0.13, unchanged from the previous year[16] - R&D expenses for the period were 41,335,925.30 yuan, down from 57,373,399.37 yuan in the previous year[24] - Other comprehensive income increased by 251.39%, an increase of 14.44 million yuan, mainly due to foreign currency translation differences[18] - Non-current asset disposal loss was CNY -1.5384 million[52] - Government subsidies recognized in the current period amounted to CNY 1.8443 million[52]

Financial Performance - The company achieved operating revenue of CNY 4,379.83 million, a year-on-year increase of 0.52%[13] - Operating profit reached CNY 878.60 million, reflecting a growth of 15.81% compared to the previous year[13] - Net profit attributable to shareholders was CNY 749.40 million, up 21% year-on-year, with earnings per share of CNY 0.76[13] - Total revenue for the year was approximately CNY 9.87 billion, with a net profit of CNY 1.78 billion, representing a year-on-year increase of 17.76%[33] - Operating cash inflow decreased by 5.01% to CNY 3.93 billion, while operating cash outflow decreased by 4.56% to CNY 3.32 billion, resulting in a net cash flow from operating activities of CNY 609 million, down 7.39%[45] - The company reported a loss of 1,818,798.95 CNY from its investment in Zhejiang Tianxian Biopharmaceutical Co. during the reporting period[56] Research and Development - The company’s R&D efforts led to the successful evaluation of multiple products, including the approval of Mifepristone tablets in March 2023[15] - The company achieved significant progress in product development, with 3 clinical trials approved and 6 ongoing, alongside 2 generic drug applications accepted and 7 projects under review[35] - The company has been enhancing its R&D capabilities, with 46 projects underway and significant advancements in formulation development, including complex formulations[35] - R&D investment amounted to ¥266,768,087.11 in 2022, reflecting a 9.61% increase from ¥243,374,020.91 in 2021[74] - R&D expenditure accounted for 6.09% of total revenue, up from 5.59% in the previous year, indicating a 0.50% increase[77] - The company is focusing on the development of new products in three major therapeutic areas, particularly in gynecology and respiratory formulations, to enrich its product line[104] - The company has multiple ongoing R&D projects aimed at obtaining drug approvals, including 12 projects in gynecology and reproductive health, which are expected to expand the product line significantly[1] Market Expansion and Strategy - The company established business connections with over 40 clients and traders across Europe, Japan, Southeast Asia, South America, the Middle East, and North Africa[9] - The company is advancing its internationalization strategy, with projects entering the FDA application phase and ongoing GMP system optimization[36] - The company aims to become one of the top ten steroid drug suppliers globally, focusing on high-value innovation and structural optimization in the pharmaceutical industry[63] - The company is actively pursuing market expansion and innovation in response to national policies encouraging research and development in the pharmaceutical sector[60] - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence[151] - The company plans to strengthen product development and enhance collaboration with distributors to expand market coverage[90] Financial Management and Investments - The investment cash inflow increased by 12.63% to CNY 868 million, while investment cash outflow decreased significantly by 47.67% to CNY 511 million, leading to a net cash flow from investing activities of CNY 358 million, a turnaround from a negative cash flow in the previous year[45] - The company has not utilized 46,896.33 million CNY of raised funds, which are currently held in a dedicated account[64] - The company raised a total of 987.36 million RMB through a private placement, with a net amount of 987.36 million RMB after deducting underwriting fees[94] - As of the reporting period, the cumulative amount of raised funds used is 548.60 million RMB, with a remaining balance of 468.96 million RMB in the special account for raised funds[94] - The company invested a total of 22,500,000 CNY during the reporting period, representing a 14.75% increase compared to the previous year's investment of 19,607,300 CNY[56] Governance and Compliance - The company has established a governance structure that complies with legal requirements, ensuring independence from major shareholders in personnel decisions[135] - The company emphasizes the importance of maintaining communication with stakeholders to balance interests and promote sustainable development[133] - The company has a dedicated supervisory board that ensures compliance and protects the rights of shareholders[131] - The company is focused on enhancing its corporate governance and compliance with regulatory standards[155] - The company adheres to information disclosure requirements, ensuring timely and accurate communication with investors[159] - The company has no significant differences in governance practices compared to legal and regulatory requirements[181] Operational Efficiency and Cost Management - The company aims to enhance production efficiency and reduce costs through the implementation of a "profit center" model and lean production tools[93] - The company is committed to optimizing its procurement processes to reduce costs through a two-tier procurement model and centralized purchasing strategies[109] - The company plans to strengthen cost control measures in response to rising management costs, including fixed asset depreciation and financial expenses[118] - The company is committed to enhancing environmental protection measures and has achieved compliance with current regulations, but anticipates potential increases in costs due to stricter future regulations[118] - The company is focused on achieving a cost advantage through green chemistry processes and efficient production organization[106] Talent Development and Management - The number of R&D personnel increased to 562, representing a growth of 7.25% compared to 2021[74] - The company is developing a comprehensive talent management strategy to cultivate a modern workforce and improve overall performance[110] - The leadership team includes members with dual degrees and expertise in engineering and economics, reflecting a diverse skill set[196][198] - The company emphasizes the importance of professional qualifications among its executives to drive strategic initiatives and operational efficiency[195] - The company is focusing on talent development to meet the demands of international competition and ensure sustainable growth[119] Industry Challenges and Risks - The company faces risks related to industry policy changes and drug price reductions, which could impact profitability[113] - The company acknowledges the high risks associated with drug research and development, including potential misalignment with market demand and increased competition post-launch, which could adversely affect profitability[142] - The company faces risks related to rising comprehensive management costs and talent shortages, which could impact operational efficiency[145] - The company reported a significant impact from national drug procurement policies, affecting pricing and sales strategies[151] - The company is actively developing new products and technologies to adapt to the national centralized procurement policy and enhance its competitive position[127]

证券代码：002332 证券简称：仙琚制药 公告编号：2023-022 浙江仙琚制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展 战略等情况，公司定于 2023 年 04 月 28 日（星期五）15:00-17:00 在"价值在线" （www.ir-online.cn）举办浙江仙琚制药股份有限公司 2022 年度网上业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 28 日（星期五）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长张宇松，总经理金炜华，财务总监王瑶华，董事会秘书张王伟，独立 董事张红英（如遇特殊情况，参会人员可能进行调整）。 浙江仙琚制药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证 ...